
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences Inc. is focused on advancing innovative therapeutic solutions for hepatitis B virus (HBV) infection, aiming to significantly enhance cure rates through multiple drug candidates that target various stages of the HBV lifecycle. The promising data from their HBV-cure program, including strong antiviral activity and favorable safety profiles for leading candidates such as ABI-5366, indicates a solid foundation for future success and potential revenue generation, with a peak sales estimate of nearly $4 billion in the U.S. Additionally, the recent $175 million equity financing reinforces the company's financial health and positions it well to sustain operations through 2027 while continuing to optimize its clinical programs.
Bears say
Assembly Biosciences Inc. faces significant challenges as it seeks to advance its clinical-stage biotechnology programs, particularly in the treatment of hepatitis B virus (HBV) infection, which is primarily responsible for its revenue generation. The company's reliance on the HBV-cure program is undermined by potential negative outcomes for its drug candidates ABI-6250 and ABI-1179/5366, leading to concerns about their viability and the ability to progress in clinical trials. Additionally, Assembly has not yet demonstrated profitability, and its historical financial losses raise red flags regarding the sustainability of its operations and ability to effectively support its therapeutic development initiatives.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares